Stimulant Drug Testing: Amphetamines, Methamphetamine, and Cocaine

Stimulant testing covers several distinct drugs and metabolites, not one interchangeable category. Amphetamine-class immunoassays and cocaine-metabolite assays have different targets, limitations, and confirmation requirements.

This guide covers amphetamine, methamphetamine, MDMA-related compounds, and cocaine testing. For the broader panel structure, see Substances and Drug Testing Panels.

Common stimulant analytes

  • Amphetamine may be a prescribed drug, a metabolite of another medication, or associated with nonmedical exposure.
  • Methamphetamine can metabolize partly to amphetamine. Some programs use additional analysis to distinguish forms or potential sources.
  • MDMA and related compounds may be included within an amphetamine-class assay or ordered separately, depending on the panel.
  • Cocaine is commonly evaluated through benzoylecgonine, a principal metabolite, rather than through a general “stimulant” screen.

A panel may include some but not all of these analytes. The report and laboratory directory are authoritative.

Why amphetamine screens need careful review

Initial amphetamine immunoassays are designed to recognize a group of chemically related compounds. Cross-reactivity varies by manufacturer. Certain prescription and over-the-counter medications can contribute to a presumptive result on some assays, while the assay may be less sensitive to other stimulant compounds.

A specific confirmatory method can distinguish amphetamine, methamphetamine, MDMA, MDA, or other targeted analytes. Confirmation greatly reduces—but does not eliminate—the need for contextual interpretation.

Methamphetamine source differentiation

Methamphetamine exists in different molecular forms, often described as d- and l-isomers. Some medications or products may be associated with a different pattern than commonly misused methamphetamine. Standard confirmation may report total methamphetamine without isomer separation. When the source is genuinely disputed and program rules permit it, specialized isomer testing may provide additional information.

Isomer analysis is not automatically included and should not be ordered reflexively. The reviewer should first verify the medication and product history, confirmed analytes, concentration criteria, and applicable rules.

Cocaine testing

Urine cocaine testing typically targets benzoylecgonine. Compared with some broad class immunoassays, cocaine-metabolite assays are generally more specific to cocaine exposure, but any result must still be evaluated under the program’s confirmation and review process.

A confirmed result does not establish the exact dose, route, time, or degree of impairment. Medical use of pharmaceutical cocaine is uncommon but possible in certain procedures and should be reviewed through an authorized medical channel.

Detection windows

The detection period depends on the drug, specimen, dose, use pattern, metabolism, test method, and cutoff. Oral fluid and blood tend to focus on more recent exposure; urine usually offers a longer window; hair can provide a longer retrospective view but does not pinpoint an exact day.

No table can guarantee when an individual will test negative. Read Drug Detection Windows Explained for the factors that shape the window.

Prescription stimulants

Medications used for attention-deficit/hyperactivity disorder, narcolepsy, or other conditions may contain amphetamine or related stimulants. Some will be expected to produce a confirmed amphetamine finding; others have different chemistry and may not appear on a standard panel.

In workplace testing, relevant prescriptions are generally reviewed by an MRO according to program rules. In clinical care, the medication list, last dose, adherence pattern, and assay coverage help interpret expected and unexpected results. The concentration alone usually cannot prove that a dose was taken exactly as prescribed.

Screening, confirmation, and reporting

  1. Collection: the specimen is obtained and identified under the applicable procedure.
  2. Initial test: an immunoassay or other screening method evaluates defined analytes at screening cutoffs.
  3. Confirmation: a specific analytical method identifies targeted drugs or metabolites after a non-negative screen when required.
  4. Review: an MRO, clinician, or other authorized professional considers legitimate explanations and program criteria.
  5. Final report: the result is reported using the program’s categories—not simply the raw screen reaction.

See Screening Versus Confirmatory Testing.

What a result cannot establish

A confirmed stimulant result does not by itself prove a substance-use disorder, workplace impairment, unsafe behavior, exact timing, or source. Likewise, a negative result does not rule out every stimulant or every exposure. It means the reported analytes did not meet the test’s criteria in that specimen.

What to review after an unexpected result

  • Was the finding presumptive or confirmed?
  • Which specific analytes and metabolites were reported?
  • Which medications and over-the-counter products were documented?
  • Was specialized isomer testing relevant and available?
  • Were specimen validity and chain-of-custody requirements satisfied?
  • What is the deadline for medical review or retesting?

Continue with Prescription Medications and Drug Testing and How to Review or Challenge a Drug-Test Result.

Sources

Last evidence review: October 29, 2026.